The role of notch in the cardiovascular system: Potential adverse effects of investigational notch inhibitors

Frontiers in Oncology

Volumn 4, Issue , 2015, Pages 1-11

  Rizzo, Paola ^a,b   Mele, Donato ^c   Caliceti, Cristiana ^a   Pannella, Micaela ^a   Fortini, Cinzia ^a   Clementz, Anthony George ^d   Morelli, Marco Bruno ^a   Aquila, Giorgio ^a   Ameri, Pietro ^e   Ferrari, Roberto ^a,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b GVM Hospitals of Care and Research   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^d DEPAUL UNIVERSITY   (United States)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer therapy; Cardiac remodeling; Cardiotoxicity; Endothelial dysfunctions; Notch inhibitors

Indexed keywords

AFATINIB; ANTHRACYCLINE; BEVACIZUMAB; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; GAMMA SECRETASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LAPATINIB; NOTCH RECEPTOR; NOTCH1 RECEPTOR; PERTUZUMANB; PROTEIN JAGGED 1; SORAFENIB; SUNITINIB; SUPEROXIDE DISMUTASE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS ASSAY; ARTICLE; CANCER PATIENT; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR SYSTEM; DOWNSTREAM PROCESSING; HEART DISEASE; HEART FUNCTION; HEART INJURY; HEART MUSCLE INJURY; HUMAN; LUNG BLOOD VESSEL; METASTASIS; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR RECURRENCE; TWO DIMENSIONAL ECHOCARDIOGRAPHY; VASCULAR SMOOTH MUSCLE; VASCULARIZATION;

EID: 85013080221     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00384     Document Type: Article

References (137)

1. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardiooncological prevention. J Natl Cancer Inst (2010) 102:14-25. doi:10.1093/jnci/ djp440.
2. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol (2010) 7:564-75. doi:10.1038/nrcardio. 2010.121.
3. Suter TM,Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J (2013) 34:1102-11. doi:10.1093/eurheartj/ehs181.
4. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 20:1215-21. doi:10.1200/JCO.20.5.1215.
5. Mele D. Diagnosis of cardiotoxiciity: role of conventional and advanced cardiovascular imaging. J Cardiovasc Echog (2012) 11:60-72.
6. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer (2003) 97:2869-79. doi:10.1002/cncr.11407.
7. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Re v (2004) 56:185-229. doi:10.1124/pr.56.2.6
8. Bulten BF, Mavinkurve-Groothuis AM, de Geus-Oei LF, de Haan AF, de Korte CL, Bellersen L, et al. Early myocardial deformation abnormalities in breast cancer survivors. Breast Cancer Res Treat (2014) 146(1):127-35. doi:10.1007/s10549-014-29974.
9. YlanenK,EerolaA,VettenrantaK,Poutanen T.Three-dimensional echocardiography and cardiac magnetic resonance imaging in the screening of long-term survivors of childhood cancer after cardiotoxic therapy. Am J Cardiol (2014) 113:1886-92. doi:10.1016/j.amjcard.2014.03.019.
10. Broeyer FJ, Osanto S, Ritsema van Eck HJ, van Steijn AQ, Ballieux BE, Schoemaker RC, et al. Evaluation of biomarkers for cardiotoxicity of anthracyclinbased chemotherapy. J Cancer Res Clin Oncol (2008) 134:961-8. doi:10.1007/ s00432-008-03728.
11. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 18:1639-42. doi:10.1038/nm.2919.
12. Broeyer FJ, Osanto S, Suzuki J, de Jongh F, van Slooten H, Tanis BC, et al. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients. Br J Clin Pharmacol (2014) 78(5):950-60. doi:10.1111/bcp.12429.
13. Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep (2009) 61:154-71. doi:10.1016/S1734-1140(09)700180.
14. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science (2009) 324:98-102. doi:10.1126/science.1164680.
15. Croquelois A, Domenighetti AA, Nemir M, Lepore M, Rosenblatt-Velin N, Radtke F, et al. Control of the adaptive response of the heart to stress via the Notch1 receptor pathway. J Exp Med (2008) 205:3173-85. doi:10.1084/jem. 20081427.
16. Ellison GM, Vicinanza C, Smith AJ, Aquila I, Leone A, Waring CD, et al. Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell (2013) 154:827-42. doi:10.1016/j.cell.2013.07.039.
17. Urbanek K, Torella D, Sheikh F, De Angelis A, Nurzynska D, Silvestri F, et al. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc Natl Acad Sci U S A (2005) 102:8692-7. doi:10.1073/pnas.0500169102.
18. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation (2010) 121:675-83. doi:10.1161/CIRCULATIONAHA.109. 902221.
19. De Angelis AA, Piegari E, Cappetta D, Marino L, Filippelli A, Berrino L, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation (2010) 121:276-92. doi:10.1161/CIRCULATIONAHA.109.895771.
20. Zeglinski M,Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: a 'dual-hit'. Exp Clin Cardiol (2011) 16:70-4.
21. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer:correlation of relapse and survivalwith amplification of the HER- 2/neu oncogene. Science (1987) 235:177-82. doi:10.1126/science.3798106.
22. Bria E, Cuppone F, Milella M,Verma S, Carlini P,Nistico C,et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther (2008) 8:1963-71. doi:10.1517/14728220802517935.
23. Milano G, Raucci A, Scopece A, Daniele R, Guerrini U, Sironi L, et al. Doxorubicin and trastuzumab regimen induces biventricular failure in mice. J Am Soc Echocardiogr (2014) 27:568-79. doi:10.1016/j.echo.2014.01.014.
24. Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc (2008) 83:197-203. doi:10.4065/83.2.197.
25. De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res (2010) 106:35-46. doi:10.1161/CIRCRESAHA.109.205906.
26. Sendur MA, Aksoy S, Altundag K. Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin (2013) 29:1015-24. doi:10.1185/03007995.2013. 807232.
27. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. J Clin Oncol (2010) 28:3422-8. doi:10.1200/JCO.2009.26.0463.
28. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol (2005) 23:7820-6. doi:10.1200/JCO.2005.13.300.
29. ElZarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS, et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One (2013) 8:e79543. doi:10.1371/journal.pone.0079543.
30. Sandoo A, Kitas GD, Carmichael AR. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer. Anticancer Res (2014) 34:1147-51.
31. Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Ambrosone CB, et al. Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. Breast Cancer (2014) 21(6):780-5. doi:10.1007/s12282-014-05431.
32. Chung AS, Kowanetz M, Wu X, Zhuang G, Ngu H, Finkle D, et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol (2012) 227(4):404-16. doi:10.1002/path.4052.
33. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet (2012) 13:654-66. doi:10.1038/nrg3272.
34. Uyttendaele H,Marazzi G,Wu G,Yan Q,Sassoon D,Kitajewski J. Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development (1996) 122:2251-9.
35. Wu J, Iwata F, Grass JA, Osborne CS, Elnitski L, Fraser P, et al. Molecular determinants of Notch4 transcription in vascular endothelium.Mol Cell Biol (2005) 25:1458-74. doi:10.1128/MCB.25.4.1458-1474.2005.
36. Shutter JR, Scully S, Fan W, Richards WG, Kitajewski J, Deblandre GA, et al. Dll4,a novel Notch ligand expressed inarterial endothelium. Genes Dev (2000) 14:1313-8.
37. Martinez JC,MullerMM,TurleyH,SteersG,ChoteauL,LiJL,et al. Nuclear and membrane expression of the angiogenesis regulator delta-like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology (2009) 54:598-606. doi:10.1111/j.1365-2559.2009.03279.x
38. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther (2013) 139:95-110. doi:10.1016/j.pharmthera.2013.02.003.
39. Borggrefe T,Liefke R. Fine-tuningof the intracellular canonical Notch signaling pathway. Cell Cycle (2012) 11:264-76. doi:10.4161/cc.11.2.18995.
40. Quillard T, Devalliere J, Coupel S, Charreau B. Inflammation dysregulates Notch signaling in endothelial cells: implication of Notch2 and Notch4 to endothelial dysfunction. Biochem Pharmacol (2010) 80:2032-41. doi:10.1016/ j.bcp.2010.07.010.
41. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest (2008) 88:11-7. doi:10.1038/labinvest.3700700.
42. Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C. Notch-1 and Notch-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Res (2011) 13:R63. doi:10.1186/bcr2900.
43. Rizzo P, Osipo C, Pannuti A, Golde T, Osborne B, Miele L. Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer. Adv Enzyme Regul (2009) 49:134-41. doi:10.1016/j.advenzreg.2009.01.008.
44. Gu JW, Rizzo P, Pannuti A, Golde T, Osborne B, Miele L. Notch signals in the endothelium and cancer "stem-like"cells: opportunities for cancer therapy. Vasc Cell (2012) 4:7. doi:10.1186/2045-824X-47.
45. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene (2008) 27:5124-31. doi:10.1038/onc. 2008.226.
46. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res (2010) 16:3141-52. doi:10.1158/1078-0432.CCR-09-2823.
47. Purow B. Notch inhibitionas a promising new approachto cancer therapy.Adv Exp Med Biol (2012) 727:305-19. doi:10.1007/978-1-4614-0899-4_23.
48. Kofler NM, Shawber CJ, Kangsamaksin T, Reed HO, Galatioto J, Kitajewski J. Notch signaling in developmental and tumor angiogenesis. Genes Cancer (2011) 2:1106-16. doi:10.1177/1947601911423030.
49. Lindner V, Booth C, Prudovsky I, Small D, Maciag T, Liaw L. Members of the Jagged/Notch gene families are expressed in injured arteries and regulate cell phenotype via alterations in cell matrix and cell-cell interaction. Am J Pathol (2001) 159:875-83. doi:10.1016/S0002-9440(10)617634.
50. Villa N,Walker L,Lindsell CE, Gasson J,Iruela-Arispe ML,Weinmaster G.Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev (2001) 108:161-4. doi:10.1016/S0925-4773(01)004695.
51. Weber DS. A novel mechanism of vascular smooth muscle cell regulation by Notch: platelet-derived growth factor receptor-beta expression? Circ Res (2008) 102:1448-50. doi:10.1161/CIRCRESAHA.108.179044.
52. Benedito R, Hellstrom M. Notch as a hub for signaling in angiogenesis. Exp Cell Res (2013) 319:1281-8. doi:10.1016/j.yexcr.2013.01.010.
53. de la Pompa JL, Epstein JA. Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev Cell (2012) 22:244-54. doi:10.1016/j.devcel.2012.01.014.
54. Gude NA, Emmanuel G, Wu W, Cottage CT, Fischer K, Quijada P, et al. Activation of Notch-mediated protective signaling in the myocardium. Circ Res (2008) 102:1025-35. doi:10.1161/CIRCRESAHA.107.164749.
55. Limana F, Esposito G, Fasanaro P, Foglio E, Arcelli D, Voellenkle C, et al. Transcriptional profiling of HMGB1-induced myocardial repair identifies a key role for Notch signaling. Mol Ther (2013) 21:1841-51. doi:10.1038/mt. 2013.137.
56. Nemir M, Metrich M, Plaisance I, Lepore M, Cruchet S, Berthonneche C, et al. The Notch pathway controls fibrotic and regenerative repair in the adult heart. Eur Heart J (2012) 35(32):2174-85. doi:10.1093/eurheartj/ehs269.
57. Oie E, Sandberg WJ, Ahmed MS, Yndestad A, Laerum OD, Attramadal H, et al. Activation of Notch signaling in cardiomyocytes during post-infarction remodeling. Scand Cardiovasc J (2010)44:359-66. doi:10.3109/14017431.2010. 511256.
58. Russell JL,Goetsch SC,Gaiano NR,Hill JA,Olson EN,Schneider JW.Adynamic Notch injury response activates epicardium and contributes to fibrosis repair. Circ Res (2011) 108:51-9. doi:10.1161/CIRCRESAHA.110.233262.
59. Schwartz SM. Role of endothelial integrity in atherosclerosis. Artery (1980) 8:305-14.
60. Iiyama K, Hajra L, Iiyama M, Li H, DiChiara M, Medoff BD, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res (1999) 85:199-207. doi:10.1161/01.RES.85.2.199.
61. Hajra L,Evans AI, Chen M,Hyduk SJ, Collins T,Cybulsky MI. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci U S A (2000) 97:9052-7. doi:10.1073/pnas.97.16.9052.
62. Ferrari R, Bachetti T, Agnoletti L, Comini L, Curello S. Endothelial function and dysfunction in heart failure. Eur Heart J (1998) 19(Suppl G):G41-7.
63. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation (2002) 105:1135-43. doi:10.1161/hc0902.104353.
64. Liuzzo G, Biasucci LM, Gallimore JR, Caligiuri G, Buffon A, Rebuzzi AG, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol (1999) 34:1696-703. doi:10.1016/S0735-1097(99) 004325.
65. Pietila KO, Harmoinen AP, Jokiniitty J,Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J (1996) 17:1345-9. doi:10.1093/oxfordjournals.eurheartj.a015068.
66. Valgimigli M,Agnoletti L, Curello S, Comini L,Francolini G, Mastrorilli F,et al. Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells: a possible link to pan-coronary syndromes. Circulation (2003) 107:264-70. doi:10.1161/01.CIR.0000045665.57256.86.
67. Agnoletti L, Curello S, Bachetti T, Malacarne F, Gaia G, Comini L, et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation (1999) 100:1983-91. doi:10.1161/01.CIR.100.19.1983.
68. Quillard T, Devalliere J, Chatelais M, Coulon F, Seveno C, Romagnoli M, et al. Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin. PLoS One (2009) 4:e8244. doi:10.1371/journal.pone.0008244.
69. Quillard T,CoupelS,CoulonF,FitauJ,Chatelais M,Cuturi MC,et al. Impaired Notch4 activity elicits endothelial cell activation and apoptosis: implication for transplant arteriosclerosis. Arterioscler Thromb Vasc Biol (2008) 28:2258-65. doi:10.1161/ATVBAHA.108.174995.
70. Walshe TE, Connell P, Cryan L, Ferguson G, Gardiner T, Morrow D, et al. Microvascular retinal endothelial and pericyte cell apoptosis in vitro: role of Hedgehog and Notch signaling. Invest Ophthalmol Vis Sci (2011) 52(7):4472-83. doi:10.1167/iovs.10-7061.
71. Takeshita K, Satoh M, Ii M, Silver M, Limbourg FP, Mukai Y, et al. Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res (2007) 100:70-8. doi:10.1161/01.RES.0000254788.47304.6e.
72. Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL, et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol (2004) 24:8813-22. doi:10.1128/MCB.24.20.8813-8822.2004.
73. Cai WX, Liang L, Wang L, Han JT, Zhu XX, Han H, et al. Inhibition of Notch signaling leads toincreased intracellular ROS byup-regulating Nox4 expression in primaryHUVECs.Cell Immunol (2014) 287:129-35. doi:10.1016/j.cellimm. 2013.12.009.
74. Jiang H, Cheng XW, Shi GP, Hu L, Inoue A, Yamamura Y, et al. Cathepsin Kmediated Notch1 activation contributes to neovascularization in response to hypoxia. Nat Commun (2014) 5:3838. doi:10.1038/ncomms4838.
75. SchoberA,Nazari-JahantighM,WeiY,BidzhekovK,GremseF,GrommesJ,et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med (2014) 20:368-76. doi:10.1038/nm.3487.
76. SandooA,van Zanten JJ,MetsiosGS,CarrollD,Kitas GD.The endotheliumand its role in regulating vascular tone. Open Cardiovasc Med J (2010) 4:302-12.
77. PatenaudeA,FullerM,ChangL,WongF,PaliourasG,ShawR,et al. Endothelialspecific Notch blockade inhibits vascular function and tumor growth through an eNOS-dependent mechanism. Cancer Res (2014) 74:2402-11. doi:10.1158/ 0008-5472.CAN-12-4038.
78. Wang L, Zhang H, Rodriguez S, Cao L, Parish J, Mumaw C, et al. Notchdependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-kappaB-dependent manner. Cell Stem Cell (2014) 15:51-65. doi:10.1016/j.stem.2014.04.021.
79. Lee KS, Kim J, Kwak SN, Lee KS, Lee DK, Ha KS, et al. Functional role of NF-kappaB in expression of human endothelial nitric oxide synthase. Biochem Biophys Res Commun (2014) 448:101-7. doi:10.1016/j.bbrc.2014.04.079.
80. Jakobsson L, Bentley K, Gerhardt H. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans (2009) 37:1233-6. doi:10.1042/BST0371233.
81. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene (2008) 27:5132-7. doi:10.1038/onc. 2008.227.
82. Funahashi Y, Shawber CJ, Vorontchikhina M, Sharma A, Outtz HH, Kitajewski J. Notch regulates the angiogenic response via induction of VEGFR-1. J Angiogenes Res (2010) 2:3. doi:10.1186/2040-2384-23.
83. Bentley K, Franco CA, Philippides A, Blanco R, Dierkes M, Gebala V, et al. The role of differential VE-cadherin dynamics in cell rearrangement during angiogenesis. Nat Cell Biol (2014) 16:309-21. doi:10.1038/ncb2926.
84. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGFVEGFR2 signalling. Nature (2012) 484:110-4. doi:10.1038/nature10908.
85. Watson O, Novodvorsky P, Gray C, Rothman AM, Lawrie A, Crossman DC, et al. Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling. Cardiovasc Res (2013) 100:252-61. doi:10.1093/cvr/cvt170.
86. Lee SH, Lee S,Yang H, Song S, Kim K, Saunders TL, et al. The Notch pathway targets proangiogenic regulator Sox17 to restrict angiogenesis. Circ Res (2014) 115(2):215-26. doi:10.1161/CIRCRESAHA.115.303142.
87. Liu H, Zhang W, Kennard S, Caldwell RB, Lilly B. Notch3 is critical for proper angiogenesis and mural cell investment. Circ Res (2010) 107:860-70. doi:10.1161/CIRCRESAHA.110.218271.
88. Dimova I, Hlushchuk R, Makanya A, Styp-Rekowska B, Ceausu A, Flueckiger S, et al. Inhibition of Notch signaling induces extensive intussusceptive neo-angiogenesis by recruitment of mononuclear cells. Angiogenesis (2013) 16:921-37. doi:10.1007/s10456-013-93665.
89. Sweet DT, Chen Z, Givens CS, Owens AP I I I, Rojas M, Tzima E. Endothelial Shc regulates arteriogenesis through dual control of arterial specification and inflammation via the Notch and nuclear factor-kappa-light-chainenhancer of activated B-cell pathways. Circ Res (2013) 113:32-9. doi:10.1161/ CIRCRESAHA.113.301407.
90. CangianoE,CavazzaC,CampoG,ValgimigliM,FrancoliniG,MalaguttiP,et al. Different clinical models of CD34 + cells mobilization in patients with cardiovascular disease. J Thromb Thrombolysis (2011) 32:1-8. doi:10.1007/s11239- 010-05438.
91. Drela E, Stankowska K, Kulwas A, Rosc D. Endothelial progenitor cells in diabetic foot syndrome. Adv Clin Exp Med (2012) 21:249-54.
92. Kwon SM, Eguchi M, Wada M, Iwami Y, Hozumi K, Iwaguro H, et al. Specific Jagged-1 signal from bone marrow microenvironment is required for endothelial progenitor cell development for neovascularization. Circulation (2008) 118:157-65. doi:10.1161/CIRCULATIONAHA.107.754978.
93. Wang L,Wang YC, Hu XB, Zhang BF, Dou GR, He F, et al. Notch-RBP-J signaling regulates the mobilization and function of endothelial progenitor cells by dynamic modulation of CXCR4 expression in mice. PLoS One (2009) 4:e7572. doi:10.1371/journal.pone.0007572.
94. Ii M, Takeshita K, Ibusuki K, Luedemann C, Wecker A, Eaton E, et al. Notch signaling regulates endothelial progenitor cell activity during recovery from arterial injury in hypercholesterolemic mice. Circulation (2010) 121:1104-12. doi:10.1161/CIRCULATIONAHA.105.553917.
95. Cao L, Arany PR, Wang YS, Mooney DJ. Promoting angiogenesis via manipulation of VEGF responsiveness with Notch signaling. Biomaterials (2009) 30:4085-93. doi:10.1016/j.biomaterials.2009.04.051.
96. Liu R, Trindade A, Sun Z, Kumar R, Weaver FA, Krasnoperov V, et al. Inhibition of Notch signaling by Dll4-Fc promotes reperfusion of acutely ischemic tissues. Biochem Biophys Res Commun (2012) 418:173-9. doi:10.1016/j.bbrc. 2012.01.002.
97. Trindade A, Djokovic D, Gigante J, Badenes M, Pedrosa AR, Fernandes AC, et al. Low-dosage inhibition of dll4 signaling promotes wound healing by inducing functional neo-angiogenesis. PLoS One (2012) 7:e29863. doi:10.1371/journal.pone.0029863.
98. Campos AH, Wang W, Pollman MJ, Gibbons GH. Determinants of Notch-3 receptor expression and signaling in vascular smooth muscle cells: implications in cell-cycle regulation. Circ Res (2002) 91:999-1006. doi:10.1161/01. RES.0000044944.99984.25.
99. WuX,ZouY,Zhou Q,Huang L,Gong H,SunA,et al. Roleof Jagged1inarterial lesions after vascular injury. Arterioscler Thromb Vasc Biol (2011) 31:2000-6. doi:10.1161/ATVBAHA.111.225144.
100. Zou S, Ren P, Nguyen M, Coselli JS, Shen YH, LeMaire SA. Notch signaling in descending thoracic aortic aneurysm and dissection. PLoS One (2012) 7:e52833. doi:10.1371/journal.pone.0052833.
101. JoutelA,CorpechotC,DucrosA,VahediK,ChabriatH,MoutonP,et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature (1996) 383:707-10. doi:10.1038/383707a0.
102. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 358:1033-41. doi:10.1016/ S0140-6736(01)061785.
103. Ozasa Y, Akazawa H, Qin Y, Tateno K, Ito K, Kudo-Sakamoto Y, et al. Notch activation mediates angiotensin II-induced vascular remodeling by promoting the proliferation and migration of vascular smooth muscle cells. Hypertens Res (2013) 36:859-65. doi:10.1038/hr.2013.52.
104. Zheng YH, Li FD, Tian C, Ren HL, Du J, Li HH. Notch gamma-secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice by multiple mechanisms. PLoS One (2013) 8:e83310. doi:10.1371/journal.pone.0083310.
105. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med (2006) 12:1075-80. doi:10.1038/ nm1459.
106. SweeneyC,MorrowD,BirneyYA,CoyleS,HennessyC,SchellerA,et al. Notch1 and 3 receptor signaling modulates vascular smooth muscle cell growth, apoptosis, and migration via a CBF-1/RBP-Jk dependent pathway. FASEB J (2004) 18:1421-3. doi:10.1096/fj.04-1700fje.
107. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol (2014) 11(5):255-65. doi:10.1038/nrcardio. 2014.28.
108. Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev (2011) 16:13-21. doi:10.1007/s10741-010-91817.
109. Dias P, Terracciano CM. Hyperpolarization-activated cyclic nucleotide-gated channels and ventricular arrhythmias in heart failure: a novel target for therapy? J Am Heart Assoc (2013) 2:e000287. doi:10.1161/JAHA.113.000287.
110. Lowes BD, Zolty R, Shakar SF, Brieke A, Gray N, Reed M, et al. Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers. J Heart Lung Transplant (2007) 26:1170-6. doi:10.1016/j.healun.2007.08.003.
111. Albert NM, Lewis C. Recognizing and managing asymptomatic left ventricular dysfunction after myocardial infarction. Crit Care Nurse (2008) 28:20-37.
112. Jhund PS, McMurray JJ. Heart failure after acute myocardial infarction: a lost battle in the war on heart failure? Circulation (2008) 118:2019-21. doi:10.1161/CIRCULATIONAHA.108.813493.
113. Kratsios P, Catela C, Salimova E, Huth M, Berno V, Rosenthal N, et al. Distinct roles for cell-autonomous Notch signaling in cardiomyocytesof the embryonic and adult heart. Circ Res (2010) 106:559-72. doi:10.1161/CIRCRESAHA.109. 203034.
114. Yu B,Song B. Notch 1 signalling inhibits cardiomyocyte apoptosis in ischaemic postconditioning. Heart Lung Circ (2013) 23(2):152-8. doi:10.1016/j.hlc.2013. 07.004.
115. Campa VM, Gutierrez-Lanza R, Cerignoli F, Diaz-Trelles R, Nelson B, Tsuji T, et al. Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. J Cell Biol (2008) 183:129-41. doi:10.1083/jcb.200806104.
116. Oh H, Bradfute SB, Gallardo TD, Nakamura T, Gaussin V, Mishina Y, et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A (2003) 100:12313-8. doi:10.1073/pnas.2132126100.
117. Jesty SA, Steffey MA, Lee FK, Breitbach M, Hesse M, Reining S, et al. c-kit+ precursors support postinfarction myogenesis in the neonatal, but not adult, heart. Proc Natl Acad Sci U S A (2012) 109:13380-5. doi:10.1073/pnas.1208114109.
118. Urbanek K, Cabral-da-Silva MC, Ide-Iwata N, Maestroni S, Delucchi F, Zheng H, et al. Inhibition of Notch1-dependent cardiomyogenesis leads to a dilated myopathy in the neonatal heart. Circ Res (2010) 107:429-41. doi:10.1161/ CIRCRESAHA.110.218487.
119. Collesi C, Zentilin L, Sinagra G, Giacca M. Notch1 signaling stimulates proliferation of immature cardiomyocytes. J Cell Biol (2008) 183:117-28. doi:10.1083/jcb.200806091.
120. Boni A, Urbanek K, Nascimbene A, Hosoda T, Zheng H, Delucchi F, et al. Notch1 regulates the fate of cardiac progenitor cells. Proc Natl Acad Sci U S A (2008) 105:15529-34. doi:10.1073/pnas.0808357105.
121. ValgimigliM,Rigolin GM,FuciliA,PortaMD, SoukhomovskaiaO,Malagutti P, et al. CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure. Circulation (2004) 110:1209-12. doi:10.1161/01. CIR.0000136813.89036.21.
122. Fortini C, Toffoletto B, Fucili A, Puppato E, Olivares A, Beltrami AP, et al. Circulating stem cell vary with NYHA stage in heart failure patients. J Cell Mol Med (2011) 15:1726-36. doi:10.1111/j.1582-4934.2010.01195.x.
123. Koyanagi M,Bushoven P,Iwasaki M,Urbich C,Zeiher AM, Dimmeler S. Notch signaling contributes to the expression of cardiac markers in human circulating progenitor cells. Circ Res (2007) 101:1139-45. doi:10.1161/CIRCRESAHA. 107.151381.
124. Li Y, Hiroi Y, Ngoy S, Okamoto R, Noma K, Wang CY, et al. Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction. Circulation (2011) 123:866-76. doi:10.1161/CIRCULATIONAHA.110.947531.
125. Li H,Yu B, ZhangY, Pan Z,Xu W, Li H. Jagged1 protein enhances the differentiation of mesenchymal stem cells into cardiomyocytes. Biochem Biophys Res Commun (2006) 341:320-5. doi:10.1016/j.bbrc.2005.12.182.
126. Sassoli C, Pini A, Mazzanti B, Quercioli F, Nistri S, Saccardi R, et al. Mesenchymal stromal cells affect cardiomyocytegrowththrough juxtacrine Notch- 1/Jagged-1 signaling and paracrine mechanisms: clues for cardiac regeneration. J Mol Cell Cardiol (2011) 51:399-408. doi:10.1016/j.yjmcc.2011.06.004.
127. Karam R, Healy BP, Wicker P. Coronary reserve is depressed in postmyocardial infarction reactive cardiac hypertrophy. Circulation (1990) 81:238-46. doi:10.1161/01.CIR.81.1.238.
128. Lassaletta AD,Elmadhun NY,Burgess TA,BianchiC,Sabe AA, Robich MP,et al. Microvascular Notch signaling is upregulated in response to vascular endothelial growth factor and chronic myocardial ischemia. Circ J (2014) 78:743-51. doi:10.1253/circj.CJ-13-0685.
129. Huang H, Huang F, Huang JP. Transplantation of bone marrowderived endothelial progenitor cells overexpressing Deltalike4 enhances functional neovascularization in ischemic myocardium. Mol Med Rep (2013) 8:1556-62. doi:10.3892/mmr.2013.1657.
130. Liebeskind DS. Collateral therapeutics for cerebral ischemia. Expert Rev Neurother (2004) 4:255-65. doi:10.1586/14737175.4.2.255.
131. Berry C, Balachandran KP, L'Allier PL, Lesperance J, Bonan R, Oldroyd KG. Importance of collateral circulation in coronary heart disease. Eur Heart J (2007) 28:278-91. doi:10.1093/eurheartj/ehl446.
132. Fung E, Tang SM, Canner JP, Morishige K, Arboleda-Velasquez JF, Cardoso AA, et al. Delta-like 4 induces Notch signaling in macrophages: implications for inflammation. Circulation (2007) 115:2948-56. doi:10.1161/ CIRCULATIONAHA.106.675462.
133. Fukuda D, Aikawa E, Swirski FK, Novobrantseva TI, Kotelianski V, Gorgun CZ, et al. Notch ligand Delta-like 4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci U S A (2012) 35(32):2174-85. doi:10.1073/pnas.1116889109.
134. Real PJ, Ferrando AA. Notch inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. Leukemia (2009) 23:1374-7. doi:10.1038/leu. 2009.75.
135. Broder H, Gottlieb RA, Lepor NE. Chemotherapy and cardiotoxicity. Rev Cardiovasc Med (2008) 9:75-83.
136. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van't Veer MB, Baaijens MH, de Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood (2007) 109:1878-86. doi:10.1182/blood-2006-07-034405.
137. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf (2008) 31:459-67. doi:10.2165/00002018-200831060-00002.